01149nam0-22003371i-450-99000846157040332120070226141530.0000846157FED01000846157(Aleph)000846157FED0100084615720070201d1993----km-y0itay50------baitaITy-------001yy1860: notizie dal regnola fine dei Borboni nelle Cronache di don Giuseppe Forgione, canonico di Gesualdo in Irpiniaa cura di Mario Bernabò Silorata e Antonio D'Erricopresentazione di Fulvio Tessitoreintroduzione di Antonio D'ErricoCava de'TirreniDi Maurostampa 1993285 p. :ill.21 cm<<I >>libri della Cava90011 rid.itaForgione,Giuseppe299155Tessitore,Fulvio<1937- >D'Errico,AntonioBernabò Silorata,Mario<1928- >ITUNINARICAUNIMARCBK990008461570403321SDI-KH 805s.i.SDISDI1860: notizie dal regno729458UNINA04466nam 2201201z- 450 991056646220332120220506(CKB)5680000000037759(oapen)https://directory.doabooks.org/handle/20.500.12854/81172(oapen)doab81172(EXLCZ)99568000000003775920202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierOncolytic Virus ImmunotherapyBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (366 p.)3-0365-2549-1 3-0365-2548-3 Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.Clinical and internal medicinebicsscMedicine and Nursingbicsscadenovirusadoptive T cell therapyantigen-agnostic vaccinationantitumor immune responsearmingbiomarkerscancercancer immune therapycancer immunotherapycancer therapyCAR T cellcheckpoint inhibitorcheckpoint inhibitorsclass I HLAclinical trialscolorectal cancercombination therapycombinatory therapyCTLA-4deliveryDNA methyltransferase inhibitor (DNMTi)epigenetic silencinggenetic modificationglioblastomaHER2herpes simplex virusHSV-1immune checkpoint blockadeimmune checkpoint inhibitorimmunoeditingimmunogenic cell deathimmunostimulatoryimmunosurveillanceimmunotherapymeasles virusmelanomamulti-stagen/aNDVnewcastle disease virusoncogenic signalingoncolyticoncolytic adenovirusoncolytic virusoncolytic virusespancreatic cancerpancreatic ductal adenocarcinomaparvovirusPD-1PD-L1personalized oncolyticvirotherapyRASreovirusretargeted virussmall moleculetargetingtropism retargetingtumortumor microenvironmenttype I interferonvaccinationvector engineeringvesicular stomatitis virusviral mimicryvirotherapyαvβ6 integrinClinical and internal medicineMedicine and NursingMarchini Antonioedt1309617Ilkow Carolina SedtMelcher AlanedtMarchini AntonioothIlkow Carolina SothMelcher AlanothBOOK9910566462203321Oncolytic Virus Immunotherapy3029458UNINA